Trial Profile
Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Aug 2023
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Sotrastaurin (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions
- 11 Aug 2023 Number of treatment arms increased from 1 to 5 by the addition of separate arms for separate doses
- 11 Aug 2023 Status changed from active, no longer recruiting to completed.
- 21 Dec 2017 Status changed from recruiting to active, no longer recruiting.